Paper Details

  1. Home
  2. Paper Details

Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.

Author: BaronJeffrey, ElshouryAmro, PrzespolewskiAmanda, WangEunice S

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

FLT3 mutations are a common and negative prognostic factor in acute myeloid leukemia (AML). While first-generation FLT3 inhibitors had limited success, second-generation inhibitors, such as quizartinib, crenolinib, and gilteritinib, have shown high potency and specificity for mutant FLT3 kinases. These newer inhibitors offer diverse kinase inhibitory properties, toxicity profiles, and pharmacokinetics, which must be considered when developing treatment plans. The integration of FLT3 inhibitors into AML treatment promises to significantly improve outcomes.
Paper Details　
Original Abstract of the Article :
Mutations of the FLT3 gene are among most common genetic abnormalities occurring in acute myeloid leukemia (AML) and are associated with dismal prognosis. Tremendous effort has been devoted to developing clinically effective FLT3 inhibitors. First generation inhibitors consisted of multi-kinase inhi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14737140.2019.1573679

データ提供：米国国立医学図書館（NLM）

FLT3 Inhibitors: A Promising Oasis in the Desert of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a serious type of blood cancer. This research explores the latest advancements in the treatment of AML, specifically focusing on FLT3 inhibitors, a class of drugs that target a specific protein involved in leukemia development. The authors review the current state of FLT3 inhibitor research, highlighting the emergence of new generation inhibitors with improved potency and specificity, offering a beacon of hope for patients with this challenging disease.

A Beacon of Hope: New Generation FLT3 Inhibitors

The study highlights the significant progress made in the development of FLT3 inhibitors. These new generation inhibitors show greater promise in effectively targeting FLT3 mutations, which are common in AML and often associated with a poor prognosis. This is a crucial development, offering a potential solution to the challenges presented by FLT3-mutant AML. The research emphasizes the importance of customizing treatment strategies based on the specific FLT3 mutation and the patient's overall condition, ensuring a more personalized and effective approach to treatment.

Navigating the Desert of AML Treatment: Toward a Brighter Future

The research on FLT3 inhibitors provides a promising glimpse into the future of AML treatment. These new generation inhibitors offer a potent weapon in the fight against this challenging disease. By continuing to refine the development and application of FLT3 inhibitors, researchers are working towards a brighter future for patients with AML, paving the way for more effective treatments and potentially even a cure.

Dr.Camel's Conclusion

This research presents a compelling case for the continued development and application of FLT3 inhibitors in the treatment of AML. These new generation inhibitors offer a beacon of hope for patients, providing a potential path to more effective and personalized therapies. This research is a testament to the ongoing quest for innovative solutions in the fight against cancer.

Date :
  1. Date Completed 2020-03-18
  2. Date Revised 2020-03-18
Further Info :

Pubmed ID

30681373

DOI: Digital Object Identifier

10.1080/14737140.2019.1573679

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.